Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Rebody Health vs ShapeIn Rx

Rebody Health
Graded #162

Higher grade

vs+7.300000000000004
ShapeIn Rx
Graded #325

Lower grade

The verdict

Rebody Health takes it — 67.7/100 to 60.4/100.

Rebody Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Rebody Health (rebodyhealth.com), operated by Compound Technologies Inc., is a transparent-pricing GLP-1 and wellness telehealth service that publishes prices up front.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueShapeIn Rx +28
46
74
Dose & formulationRebody Health +31
88
57
Clinical oversightRebody Health +21
81
60
Labs & monitoringRebody Health +1
53
52
FulfillmentRebody Health +22
84
62
Contract termsRebody Health +14
55
41
Rebody Health · left barShapeIn Rx · right bar

The numbers

MetricRebody HealthShapeIn Rx
WeighScore67.7/10060.4/100
GradeCC
Scorecard rank#162#325
Semaglutide$200/mo (starting dose, compounded)$199/mo (compounded)
Tirzepatide$250/mo (starting dose, compounded)Not disclosed
Coverage47 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Rebody Health

Graded #162 · C

Strengths

  • Publishes transparent, dose-based pricing up front on a public pricing page, so you can see costs without signing up
  • Offers compounded semaglutide and tirzepatide as both weekly injections and daily oral 'melt' tablets
  • Also carries brand-name Wegovy and Zepbound for patients who want FDA-approved products
  • Clear plan-term vs dose-tier structure; the refill price is shown before each shipment, plus $50 off the first month
  • Names its operating company (Compound Technologies Inc.) and references LegitScript approval

Where it loses points

  • Individual compounding pharmacies are not named on the marketing site
  • Not available in Massachusetts, Rhode Island, or Vermont
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
  • Dose-scaled pricing means the monthly cost can rise as your prescribed dose increases
ShapeIn Rx

Graded #325 · C

Strengths

  • One of the few telehealth providers offering compounded liraglutide as a daily alternative to weekly injections
  • Semaglutide is compounded with B12, and the combination is stated plainly
  • Publishes a street address and a staffed phone line with hours
  • States openly that telemedicine is limited to jurisdictions where its providers are licensed, rather than claiming all 50
  • LegitScript certification verified against the issued seal, not just the badge

Where it loses points

  • Advertises Trusted by 150k Americans and Excellent 4.8 with 150k happy customers, and neither figure is attributable to a verifiable review profile
  • No state list is published, only a statement that coverage is limited and a note that partner pharmacies may operate in all 50 states
  • The struck-through $199 next to $149 on the homepage reads as a discount but the two prices are different medications
  • Claims No Hidden Fees and No Monthly Membership while the Terms state subscriptions automatically renew
  • No compounding pharmacy is named, only US-Certified Pharmacy

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard